• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Phase II trial for F2G’s antifungal drug following EU approval europeanpharmaceuticalreview
    January 13, 2017
    The European Medicines Agency (EMA) Committee for Orphan Medicinal Products has granted orphan drug status to UK biotech firm F2G’s lead clinical candidate, F901318, for the treatment of invasive Aspergillosis and rare mould infections caused by Scedospor

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service